Anticoagulants play a crucial role in modern medicine, especially for patients at risk of developing blood clots. Two of the most commonly prescribed anticoagulants are Eliquis (apixaban) and Xarelto (rivaroxaban). Both medications belong to a class of drugs known as direct oral anticoagulants (DOACs) and are used to reduce the risk of stroke and blood clots in patients with conditions such as atrial fibrillation or venous thromboembolism. The choice between Eliquis and Xarelto can be a significant decision for both patients and healthcare providers. Factors such as efficacy, safety profiles, dosing regimens, and potential drug interactions must be considered. Each medication has its unique characteristics that can influence treatment decisions…